Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Analysis-2027

TUMOR NECROSIS FACTOR (TNF) INHIBITOR DRUGS MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027

© Coherent market Insights. All Rights Reserved

REPORT DESCRIPTION Tumor Necrosis Factor (TNF) Inhibitor Drugs Market - Overview Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Drivers Leading manufacturers are engaged in the development and manufacture of new products as well as biosimilars in the global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market over the forecast period. This factor is expected to aid in growth of the market over the forecast period.

For instance, Eticovo, a second biosimilar of Enbrel, manufactured by Samsung Bioepis Co., Ltd, was approved by the U.S. FDA in May 2019 and the cost of Eticovo is US$ 1,500 less than the branded medicine (Enbrel costs around US$ 5,000 for per month supply).

Tumor Necrosis Factor (TNF) inhibitors are class of medications used for the management of inflammatory arthritis. These target the TNF- alpha, a component of the immune system that is responsible for inflammation in the body. Currently, five inhibitors are available in the market namely, etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), certolizumab (cimzia), and golimumab (simponi). These are prescribed only for autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis.

Biosimilars for the already marketed drug have been approved by the U.S. Food and Drug Administration (U.S. FDA). For instance, etanercept (brand name – Enbrel) manufactured by Amgen Inc. has two biosimilars i.e. etanercept- szzs (erelzi) manufactured by Novartis AG and etanercept – ykro (eticovo) manufactured by Samsung Bioepis Co., Ltd. Browse Research Reports: https://www.coherentmarketinsights.com/ongoing-insight/tumornecrosis-factor-inhibitor-drugs-market-3463 © Coherent market Insights. All Rights Reserved

REPORT DESCRIPTION Moreover, the first biosimilar of Enbrel i.e. Erelzi, manufactured by Novartis AG, is available in the form of a sensoready pen with an inbuilt autoinjector, which is beneficial for patients suffering from arthritis and cannot work properly with their limbs. Renflexis (biosimilar of infliximab) was introduced in the U.S market by Merck & Co. in July 2018, at a list price of US$ 753.39 which represents a 35% discount to the current list price of Remicade, its reference product.

Increasing prevalence of autoimmune diseases around the globe is expected to foster the market growth of tumor necrosis factor (TNF) inhibitors drugs. For instance, according to Centers for Disease Control and Prevention (CDC), 2017, around 54.4 million people in the U.S. are suffering from some form of arthritis during (2013 – 2015).

Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Restraints According to National Center for Biotechnology Information (NCBI), 2019, it has been observed that 50% of the population suffering from autoimmune diseases worldwide, discontinue the use of TNF inhibitors after one year of use as only 5-10% of the population showed positive response to TNF inhibitors while the remaining people show disease activity or severe side effects even after the treatment with TNF inhibitors. Moreover, availability of alternatives drugs that belong to a different class available in the market is also expected to hinder the market growth. For instance, Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) approval in 2017, for Xeljanz (tofacitinib).

Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/3463 Š Coherent market Insights. All Rights Reserved

REPORT DESCRIPTION Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Regional Analysis North America is expected to hold the dominant position in the global tumor necrosis factor inhibitor drugs market over the forecast period, owing to increasing development and launches of new products in the region. For instance, under a global biosimilars development and commercialization agreement between Merck and Samsung Bioepis Co., Ltd., Renflexis (biosimilar of Remicade (infliximab)) received the U.S. FDA approval in 2019 and was the first medicine to be available in the U.S. as a TNF inhibitor.

Moreover, Amgen Inc. also announced the U.S. FDA approval for avsola in 2019 (infliximab-axxq) for all approved indications of the reference product, Remicade (infliximab) in the U.S. Also, an oral PDE4 inhibitor for the treatment of adult patients with mucositis (mouth ulcers) associated with behçet’s disease, a rare disorder that causes blood vessel inflammation throughout the body. Otezla is the first drug to be approved for this use in the U.S., providing a treatment option for behçet’s disease, many of whom develop mouth ulcers as a result of the condition.

Increasing incidence of autoimmune diseases in the population is expected to be another factor supporting the growth of North America in the global tumor necrosis factor inhibitor drugs market. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2017, around 54.4 million adults in the U.S. were suffering from arthritis, which equals about 25% of the total population while, around 1.3 million people, 294,000 people and 0.6 to 2.4 million people over 15 years of age in the U.S were suffering from rheumatoid arthritis.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3463 © Coherent market Insights. All Rights Reserved

ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele.

SERVICES INDUSTRY ANALYSIS

CUSTOMIZED RESEARCH

SYNDICATED RESEARCH

MARKET INTELLIGENCE SERVICES

CONSULT STUDIES

COUNTRY SPECIFIC STUDIES

Š Coherent market Insights. All Rights Reserved

ABOUT CMI SECTOR COVERAGE

BIOTECHNOLOGY

CLINICAL DIAGNOSTIC

HEALTHCARE IT

MEDICAL DEVICES

MEDICAL IMAGING

PHARMACEUTICAL

OUR CLIENTS

 Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators

 Private and Government organization

 Distributors, Retailors and Value Added Resellers

 Outsourcing Companies

 Healthcare IT Solutions Developers

 Universities and Business Schools.

© Coherent market Insights. All Rights Reserved

KEY STATS

RESEARCH SOLUTIONS

100+

FEASIBILITY STUDIES

Insights Published Per Year

GLOBAL REPORTS

150+

Consulting Projects Till Date

COUNTRY ANALYSIS CONSULT PROJECTS

125+

Clients Worldwide Per Year

110+

SURVEY RESEARCH

EXCEL FORECAST DATABASE

CUSTOMIZED SOLUTIONS

COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS

Analysts and Contract Consultants

Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702

Š Coherent market Insights. All Rights Reserved